Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 9/20 | 0.48 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394372 | 0.92 | TOP2A (0.49) | TOP2ATOP2BPOLBRAD52KDM4E | |
| SCHEMBL5398721 | 0.91 | TOP2A (0.47) | TOP2ATOP2BPOLBRAD52PARP1 | |
| SCHEMBL5404233 | 0.90 | TOP2A (0.46) | TOP2ATOP2BPOLBRAD52PARP1 | |
| SCHEMBL5401693 | 0.89 | TOP2A (0.43) | TOP2ATOP2BPARP1 | |
| SCHEMBL5401753 | 0.85 | TOP2A (0.40) | TOP2ATOP2BPARP1KDM1AKMT2A | |
| SCHEMBL5405656 | 0.84 | PARP1 (0.44) | TOP2ATOP2BPOLBRAD52PARP1 | |
| SCHEMBL5398724 | 0.82 | TOP2A (0.47) | TOP2ATOP2BPOLBRAD52KDM4E | |
| SCHEMBL5401696 | 0.81 | TOP2A (0.43) | TOP2ATOP2BPARP1KDM1A | |
| SCHEMBL5404239 | 0.81 | TOP2A (0.46) | TOP2ATOP2BPOLBRAD52KDM4E | |
| SCHEMBL5440209 | 0.79 | TOP2A (0.39) | TOP2ATOP2BPOLBKDM4EKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230105-B2 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2007-06-12 | — | — | US | disclosed |
| US-20050222167-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222167-A1 | 9-aminoacridine derivatives and process for the preparation thereof | PARP9, CASP9, AMPD2 | TOP2A 131/4885TOP2B 209/4885POLB 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.